BridgeMD
New treatment option for Infertility
Official title Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.
ClinicalTrials.gov ID: NCT07242534
What this study is testing
What is Semaglutide?
Semaglutide is an investigational medicine, being studied as a potential treatment for infertility.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a randomized, controlled clinical trial with a two-sided superiority hypothesis. The study evaluates whether a 12-week pre-treatment with semaglutide prior to ovarian stimulation improves the number of good-quality blastocysts in overweight and obese women undergoing in vitro fertilization (IVF), compared to no pre-treatment.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 38, women only
You may be able to join if
- ≤ 38 years
- AMH \>= 1 ng/mL or AFC \>= 6
- Body mass index (BMI) between 27 kg/m2 and 40 kg/m2
- Scheduled for IVF with freeze-all strategy
You likely can't join if
- Severe male factor (sperm concentration \<5M/mL)
- Type 2 diabetes mellitus
- Prior use of GLP-1 Ras within the past year
- Uncontrolled thyroid disorders
- Contraindications to IVF or semaglutide treatment
- Patients with chronic inflammatory diseases
See the full eligibility criteria
- ≤ 38 years
- AMH \>= 1 ng/mL or AFC \>= 6
- Body mass index (BMI) between 27 kg/m2 and 40 kg/m2
- Scheduled for IVF with freeze-all strategy
- Severe male factor (sperm concentration \<5M/mL)
- Type 2 diabetes mellitus
- Prior use of GLP-1 Ras within the past year
- Uncontrolled thyroid disorders
- Contraindications to IVF or semaglutide treatment
- Patients with chronic inflammatory diseases
- Family history of hereditary or chromosomal diseases
- Use of glucocorticoids or immunosuppressants
- PGT-A
- Use of medications affecting metabolism or inflammation
The study team makes the final eligibility decision.
Where it's taking place
- Sabadell, Barcelona, Spain
- Sant Cugat del Vallès, Barcelona, Spain
- Reus, Tarragona, Spain
- Barcelona, Spain
- Tarragona, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 38 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Sabadell, Barcelona, Spain; Sant Cugat del Vallès, Barcelona, Spain; Reus, Tarragona, Spain; Barcelona, Spain; Tarragona, Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.